These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3308 related items for PubMed ID: 26159280

  • 21. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N, Tsochatzis E.
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [Abstract] [Full Text] [Related]

  • 22. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease.
    Abrams GA, Kunde SS, Lazenby AJ, Clements RH.
    Hepatology; 2004 Aug; 40(2):475-83. PubMed ID: 15368453
    [Abstract] [Full Text] [Related]

  • 23. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH.
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [Abstract] [Full Text] [Related]

  • 24. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, Provenzale D, Choi SS, Moylan CA, Hunt CM.
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [Abstract] [Full Text] [Related]

  • 25. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
    Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, De Vincentis A, Dell'Unto C, Vorini F, Morini S, Riva E, Picardi A.
    Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
    [Abstract] [Full Text] [Related]

  • 26. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
    Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J.
    Curr Pharm Des; 2013 Aug; 19(29):5280-96. PubMed ID: 23394096
    [Abstract] [Full Text] [Related]

  • 27. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM, Day CP.
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [Abstract] [Full Text] [Related]

  • 28. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR, Nguyen MH, Lim JK.
    World J Gastroenterol; 2016 Oct 07; 22(37):8294-8303. PubMed ID: 27729736
    [Abstract] [Full Text] [Related]

  • 29. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis.
    Tan CH, Al-Kalifah N, Lee WJ, Ser KH, Lee YC, Chen JC.
    Asian J Surg; 2019 Jan 07; 42(1):203-208. PubMed ID: 29804707
    [Abstract] [Full Text] [Related]

  • 30. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O, Charlton M.
    Clin Liver Dis; 2018 Feb 07; 22(1):201-211. PubMed ID: 29128057
    [Abstract] [Full Text] [Related]

  • 31. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L, Adams LA.
    Int J Mol Sci; 2016 May 20; 17(5):. PubMed ID: 27213358
    [Abstract] [Full Text] [Related]

  • 32. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T, Japanese Society of Gastroenterology, Japan Society of Hepatology.
    J Gastroenterol; 2015 Apr 20; 50(4):364-77. PubMed ID: 25708290
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA, Vere CC, Rogoveanu I, Streba CT.
    World J Gastroenterol; 2015 Apr 14; 21(14):4103-10. PubMed ID: 25892859
    [Abstract] [Full Text] [Related]

  • 35. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 14; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan 14; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 38. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A, Elahmedi M, Alswat K, Arafah M, Fagih M, Lee J.
    Surg Obes Relat Dis; 2017 Sep 14; 13(9):1599-1609. PubMed ID: 28600116
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 166.